These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38135534)

  • 1. Association of thymidine kinase-1 with prostate cancer.
    Jiang C; Zhou W; Wang L; Ke C
    Asian J Surg; 2024 Feb; 47(2):1302-1303. PubMed ID: 38135534
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumour markers as prognostic aids in prostatic carcinoma.
    Lewenhaupt A; Ekman P; Eneroth P; Nilsson B
    Br J Urol; 1990 Aug; 66(2):182-7. PubMed ID: 1697204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymidine Kinase-1 as Additional Diagnostic Marker of Prostate Cancer.
    Hanousková L; Řezáč J; Veselý Š; Průša R; Kotaška K
    Clin Lab; 2020 Jun; 66(6):. PubMed ID: 32538039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer.
    Lundgren PO; Tribukait B; Kjellman A; Norming U; Jagarlmudi K; Gustafsson O
    Prostate; 2022 Jun; 82(8):911-916. PubMed ID: 35294068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenovirus-mediated suicide-gene therapy using the herpes simplex virus thymidine kinase gene in cell and animal models of human prostate cancer: changes in tumour cell proliferative activity.
    Cheon J; Kim HK; Moon DG; Yoon DK; Cho JH; Koh SK
    BJU Int; 2000 Apr; 85(6):759-66. PubMed ID: 10759680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of AroCell TK 210 ELISA with Prostate Health Index or prostate-specific antigen density can improve the ability to differentiate prostate cancer from noncancerous conditions.
    Jagarlamudi KK; Zupan M; Kumer K; Fabjan T; Hlebič G; Eriksson S; Osredkar J; Smrkolj T
    Prostate; 2019 Jun; 79(8):856-863. PubMed ID: 30889628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Thymidine Kinase 1 - Potential Prostate Cancer Biomarker: A Clinical Study.
    Rezac J; Hanouskova L; Vesely S; Kotaska K; Kantorova A; Linhartova A; Fiala V; Soukup V; Capoun O
    Anticancer Res; 2023 Apr; 43(4):1675-1680. PubMed ID: 36974824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate specific acid phosphatase versus five other possible tumour markers: a comparative study in men with prostatic carcinoma.
    Larson A; Fritjofsson A; Norlén BJ; Gronowitz JS; Ronquist G
    Scand J Clin Lab Invest Suppl; 1985; 179():81-8. PubMed ID: 2417306
    [No Abstract]   [Full Text] [Related]  

  • 9. Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker.
    Jagarlamudi KK; Hansson LO; Eriksson S
    BMC Cancer; 2015 Feb; 15():66. PubMed ID: 25881026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice.
    Timme TL; Hall SJ; Barrios R; Woo SL; Aguilar-Cordova E; Thompson TC
    Cancer Gene Ther; 1998; 5(2):74-82. PubMed ID: 9570298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suicide gene therapy for prostate cancer using a replication-deficient adenovirus containing the herpesvirus thymidine kinase gene.
    Shalev M; Miles BJ; Thompson TC; Ayala G; Butler EB; Aguilar-Cordova E; Kadmon D
    World J Urol; 2000 Apr; 18(2):125-9. PubMed ID: 10854147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer.
    Tribukait B; Lundgren PO; Kjellman A; Norming U; Nyman CR; Jagarlmundi K; Gustafsson O
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models.
    Eastham JA; Chen SH; Sehgal I; Yang G; Timme TL; Hall SJ; Woo SL; Thompson TC
    Hum Gene Ther; 1996 Mar; 7(4):515-23. PubMed ID: 8800746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer.
    Kubo H; Gardner TA; Wada Y; Koeneman KS; Gotoh A; Yang L; Kao C; Lim SD; Amin MB; Yang H; Black ME; Matsubara S; Nakagawa M; Gillenwater JY; Zhau HE; Chung LW
    Hum Gene Ther; 2003 Feb; 14(3):227-41. PubMed ID: 12639303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micro-PET/CT monitoring of herpes thymidine kinase suicide gene therapy in a prostate cancer xenograft: the advantage of a cell-specific transcriptional targeting approach.
    Johnson M; Sato M; Burton J; Gambhir SS; Carey M; Wu L
    Mol Imaging; 2005; 4(4):463-72. PubMed ID: 16285908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prostate cancer gene therapy].
    Nasu Y; Abarzua F; Kumon H
    Nihon Rinsho; 2005 Dec; 63 Suppl 12():544-7. PubMed ID: 16416850
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants.
    Pantuck AJ; Matherly J; Zisman A; Nguyen D; Berger F; Gambhir SS; Black ME; Belldegrun A; Wu L
    Hum Gene Ther; 2002 May; 13(7):777-89. PubMed ID: 11975845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis.
    Sivridis E; Giatromanolaki A; Papadopoulos I; Gatter KC; Harris AL; Koukourakis MI
    Br J Cancer; 2002 May; 86(9):1465-71. PubMed ID: 11986782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of gene therapy for prostate and bladder cancer.
    Herman JR; Lerner SP
    Int J Urol; 1997 Sep; 4(5):435-40. PubMed ID: 9354942
    [No Abstract]   [Full Text] [Related]  

  • 20. CL1-SR39: A noninvasive molecular imaging model of prostate cancer suicide gene therapy using positron emission tomography.
    Pantuck AJ; Berger F; Zisman A; Nguyen D; Tso CL; Matherly J; Gambhir SS; Belldegrun AS
    J Urol; 2002 Sep; 168(3):1193-8. PubMed ID: 12187266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.